Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 236

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent

Open access
Merchant, Mark, Ma, Xiaolei, Maun, Henry R., Zheng, Zhong, Peng, Jing, Romero, Mally, Huang, Arthur, Yang, Nai-ying, Nishimura, Merry, Greve, Joan, Santell, Lydia, Zhang, Yu-Wen, Su, Yanli, Kaufman, Dafna W., Billeci, Karen L., Mai, Elaine, Moffat, Barbara, Lim, Amy, Duenas, Eileen T., Phillips, Heidi S., Xiang, Hong, Young, Judy C., Vande Woude, George F., Dennis, Mark S., Reilly, Dorothea E., Schwall, Ralph H., Starovasnik, Melissa A., Lazarus, Robert A., Yansura, Daniel G. · 2013 · Proceedings of the National Academy of Sciences

Abstract

Significance: Therapeutic antibodies have revolutionized the treatment of human disease. Despite these advances, antibody bivalency limits their utility against some targets. Here, we describe the development of a one-armed (monovalent) antibody, onartuzumab, targeting the receptor tyrosine kinase MET. While initial screening of bivalent antibodies produced agonists of MET, engineering them into monovalent antibodies produced antagonists instead. We explain the structural basis of the mechanism of action with the crystal structure of onartuzumab antigen-binding fragment in complex with MET and HGF-β. These discoveries have led to an additional antibody-based therapeutic option and shed light on the underpinnings of HGF/MET signaling.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1073/pnas.1302725110

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 236

Metadata

Authors
Merchant, M., Ma, X., Maun, H. R., Zheng, Z., Peng, J., Romero, M., Huang, A., Yang, N.-Y., Nishimura, M., Greve, J., Santell, L., Zhang, Y.-W., Su, Y., Kaufman, D. W., Billeci, K. L., Mai, E., Moffat, B., Lim, A., Duenas, E. T., Phillips, H. S., Xiang, H., Young, J. C., Vande Woude, G. F., Dennis, M. S., Reilly, D. E., Schwall, R. H., Starovasnik, M. A., Lazarus, R. A., & Yansura, D. G.
Venue
Proceedings of the National Academy of Sciences
Published
2013-07-23
Volume
110
Issue
32
Pages
E2987-96
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
OpenAlex
W2059992550
Cited by
236
References
6
FWCI
17.35
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent. https://app.cochat.ai/papers/10.1073/pnas.1302725110
The paper
Merchant, M., Ma, X., Maun, H. R., Zheng, Z., Peng, J., Romero, M., Huang, A., Yang, N.-Y., Nishimura, M., Greve, J., Santell, L., Zhang, Y.-W., Su, Y., Kaufman, D. W., Billeci, K. L., Mai, E., Moffat, B., Lim, A., Duenas, E. T., . . . Yansura, D. G. (2013). Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1302725110

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.